March 29 (Reuters) - Mylan NV said on Wednesday its application to market a generic copy of GlaxoSmithKline Plc's blockbuster inhaled lung drug Advair was rejected by the U.S. Food and Drug Administration.
The drugmaker did not disclose the reason behind the rejection.
Advair has generated more than $1 billion in annual sales since 2001. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar)
Tesla's loss of $328.3 billion this year in stock value certainly hurts. But it's only the second-largest market value loss in the S&P 500.
On paper, Mark Zuckerberg is Meta’s lowest-paid employee, with a $1 dollar salary and no bonus.
Microsoft, which overtook Apple as the world's most valuable company earlier this year, is looking to cement its AI market leadership.
You'll only find seven different stocks in this billionaire's portfolio, and only one of them is a "big tech" company.
With rising inflation, American consumers are increasingly turning to the Chinese e-commerce platform Temu for their shopping needs. With its enticing tagline “Shop like a billionaire,” Temu has captured 17% of the U.S. market share, posing a challenge to traditional American retailers such as Amazon.com Inc., Dollar Tree Inc. and Five Below Inc. The rise highlights the lucrative and disruptive nature of startups. Owned and operated by PDD Holdings Inc. (NASDAQ:PDD), Temu offers a wide range of
These stocks all deserve to be trading at far higher prices, and it may not be too long before they start to rally.
This growth ETF has nicely outperformed the S&P 500 since its inception.
Bitcoin block subsidies were recently reduced by half for the fourth time in history, and halving events have always led to significant price appreciation.
One of Capitol Hill's most-active stock traders is sending a company with well-defined competitive advantages -- that also happens to be on the verge of its first-ever stock split -- to the chopping block.
This company's exciting technology is protected by more than 100 patents.